ArticleJournal of managed care & specialty pharmacy2025

Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States.

Mohsen Yaghoubi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.